Portada Simposios - Supplements - Haematologica

84 Haematologica (ed. esp.), volumen 85, supl. 2, octubre 2000
11. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J
et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant
human interleukin-2 to treat leukemia relapse after allogeneic
bone marrow transplantation. Blood 1996; 87: 2195-2204.
12. Giralt SA, Champlin RE. Leukemia Relapse After Allogeneic Bone Marrow
Transplantation. Blood 1994; 84: 3603-3612.
13. Mackinnon S, Papadopoulos EB, Caralasi MH, Reich L, Collins RH,
Boulad F et al. Adoptive immunotherapy evaluating escalating doses
of donor leukocytes for relapse of chronic myeloid leukemia after bone
marrow transplantation: separation of graft-versus-leukemia responses
from graft-versus-host disease. Blood 1995; 86: 1261-1268.
14. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al.
Lymphohematopoietic graft-versus-host reactions can be induced without
graft-versus-host disease in murine mixed chimeras stablished
with a cyclophosphamide based non-myeloabplative conditioning regimen.
Biology of Blood and Marrow Transplantation 1999; 5: 133-140.
15. Ildtad ST, Sachs DH. Reconstitution wtih syngeneic plus allogeneic or
xenogeneic bone marrow leads to specific acceptance of allografts and
xenografts. Nature 1984; 307: 168-170.
16. Slavin S, Fuks Z, Kaploin H, Strober S. Transplantation of allogeneic
bone marrow without graft vs host disease using total lymphoid irradiation.
J Exp Med 1978; 147: 963-972.
17. Tomita Y, Sachs DH, Kahn A, Sykes M. Additional m-Ab injections can
replace thymic irratiation to allow indiction of mixed chimerism and tolerance
in mice receiving bone marrow transplantation after conditioning
with anti-T cell m-Abs and 3 Gy whole body irradiation. Transplantation
1996; 61: 469-475.
18. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels
of allogeneic hematopoietic reconstitution and donor specific tolerance
without myelosuppressive conditioning. Nat Med 1997; 3: 783-787.
19. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM
et al. Mixed lymphohaemopoietic chimaerism and graft versus lymphoma
effects after non-myeloabplative therapy and HLA mismatched
bone marrow transplantation. Lancet 1999; 353: 1755-1759.
20. Díez-Martín JL, Forés R, Jiménez A, Martino R, Pérez de Oteyza J, Urbano-Ispizua
A et al. Utilización de los linfocitos del donante como tratamiento
de la recaída tras un alotrasplante en las leucemias agudas
(LA). Registro del Grupo Español de Trasplante Hemopoyético. Methods
and Findings in Experimental and Clinical Pharmacology 2000;
22 (Supl. 1): 23-31.
21. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R
et al. Donor leukocyte infusions in 140 patients with relapsed malignancy
after allogeneic bone marrow transplantation. J Clin Oncol
1997; 15: 433-444.
22. Guinan E. Costimulatory blockade as a mechanism of inducing tolerance
in the allograft setting. En: Schechter GP, Hoffman R, Schrier SL,
Bajus JL, eds. Hematology 1999. American Society of Hematology Education
Program Book. Washington, 1999; 383-388.
23. Storb R, Yu C, Zaucha M, Deeg J, Goeorges G, Kiem HP et al. Stable mixed
hematopoietic chimerism in dogs given donor antigen, CTLA4-Ig,
and 100 cGy total body irradiation before and farmacologic immunosuppresion
after marow transplant. Blood 1999; 94: 2523-2529.
24. Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD, Singer GG, ILDtad
ST. Mixed Allogeneic chimerism induced by a sublethal approach
prevents autoimmune diabetes and reverses insulinitis in nonobese diabetic
mice (NOD). J Immunol 1996; 156: 380-387.
25. Kawai T, Cosimi AB, Calvin RB, Powelson J, Eason J, Kozlowski T et al.
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus
monkeys. Transplantation 1997; 59: 256-263.
26. Santos GW, Sensenbrenner LL, Burke PJ, Mullins GM, Blas WB, Tutschka
PJ et al. The use of cyclophosphammide for clinical marrow transplantation.
Transplantation Proceedings 1972; 4: 559-565.
27. Huss R, Deeg JH, Gooley T, Bryant E, Leisenring W, Clift R et al. Effect
of mixed chimerism on graft-versus-host disease, disease recurrence
and survival after HLA-identical marrow transplantation for aplastic
anemia or chronic myelogenous leukemia. Bone Marrow Transplantation
1996; 18: 767-773.
28. Petz LD, Yam P, Wallace RB, Stock AD, deLange G, Knowlton RG et al.
Mixed hematopoietic chimerism following bone marrow transplantation
for hematologic malignancies. Blood 1987; 70: 1331-1338.
29. Marmont AM, Horowitz MM, Gale RP, Sabozinski K, Ash RC, Van Bekkum
W et al. T-cell depletion of HLA identical transplants in leukemia.
Blood 1991; 78: 2120-2128.
30. Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC.
Natural history of mixed chimerism after bone marrow transplantation
with CD6-depleted allogeneic marrow: a stable equilibrium. Blood
1990; 75: 296-303.
31. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M
et al. Persistence of mixed chimerism in patients transplanted for the
treatment of Thalassemia. Blood 1996; 87: 3494-3501.
32. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P et al.
Chimerism and donor specific non-reactivity 27 to 29 years after kidney
allotransplantation. Transplantation 1993; 55: 1272-1277.
33. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C et
al. T-cell depleted bone marrow transplantation and delayed T-cell
add-back to control acute GVHD and conserve a graft-versus-eukemia
effect. Bone Marrow Transplantation 1998; 21: 543-551.
34. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M et al.
T-cell depleted allogeneic bone marrow transplantation for acute leukaemia
using campath-1 antibodies and post-transplant administration
of donor’s peripheral blood lymphocytes for prevention of relapses.
Br J Haematol 1995; 89: 506-515.
35. McSweeney P, Niederwieser D, Shizuru J, Molina A, Wagner J, Minor S
et al. Outpatient allografting with minimally myelosuppressive, immunosuppressive
conditioning of low dose TBI and post-grafting cyclosporine
and mycophenolate mofetyl. Blood 1999; 94 (Supl. 1): 393a.
36. Spitzer T, MacAfee S, Sackstein R, Colby C, Toh HC, Multani P et al. Intentional
induction of mixed chimerism and achievement of antitumor
responses after non-myeloablative conditioning therapy and HLA-matched
donor bone marrow transplantation for refractory hematologic
malignancies. Biology of Blood and Marrow Transplantation 2000; 6:
309-320.
37. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic
hematopoietic stem cell transplantation as treatment of hematologic
neoplasia. Haematologica 2000; 85: 304-313.
38. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O’Brien S
et al. Transplant-Lite induction of graft versus malignancy using fludarabine
based non ablative chemotherapy and allogeneic blood progenitor
cell transplantation as treatment for lymphoid malignancies.
J Clin Oncol 1998; 16: 2817-2824.
39. Childs R, Contentin N, Clave E, Bahceci E, Hansel N, Boland C et al.
Reduced toxicity and transplant related mortality following non-myeloablative
allogenei peripheral blood stem cell transplantation for malignant
diseases. Blood 1999; 94 (Supl. 1): 393a.
40. Slavin S. Comunicación Oral. 26 annual meeting of the EBMT. Innsbruck
March 2000.
41. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D et al. Allogeneic
hematopoietic stem cell transplantats after immune-ablative
preparative regimen. A report of 92 patients. Blood 1999; 94 (Supl. 1):
348a.
42. Molina A, McSweeney P, Malloney DG, Sandmayer B, Bensinger W,
Nash R et al. Non-myeloablative peripheral blood stem cell allografts
following cytoreductive autotransplants for treatment of multiple myeloma.
Blood 1999; 94 (Supl. 1): 347a.
43. Hernández-Navarro F, de la Serna J, Díez-Martín JL, Hernández D, Llamas
P, Lahuerta JJ et al. Trasplante alogénico de progenitores hematopoyéticos
tras acondicionamiento no mieloablativo en pacientes con
neoplasias hematológicas avanzadas. Resultados preliminares de un estudio
cooperativo. Methods and Findings in Experimental and Clinical
Pharmacology 2000; 22 (Supl. 1): 83-86.
44. Garban F, Attal M, Rossi JF, Sotto J. High efficiency of non-myeloablative
allogeneic stem cell transplantation in poor prognosis myeloma patients.
Blood 1999; 94 (Supl. 1): 347a
45. Mitchell E, Horwiz A, Barrett J, Childs R, Miller JA, Leitman SF et al.
Non-myeloablative T-cell depleted allogeneic peripheral blood stem cell
transplantation for patients with chronic granulomatous disease. Blood
1999; 94 (Supl. 1): 710a.
46. Craddock C, Hughes T, Johnston R, Kreiter S, Bardy P, Apperley J et al.
Engraftment of T-depleted allogeneic peripheral blood stem cells using
a non-myeloablative conditioning regimen. Blood 1999; 94 (Supl. 1):
394a.
47. Russell NH, Cull G, Byrne JL, Stainer C, Rebello P, Hale G et al. Evaluation
of non-myeloablative conditioning combining BEAM with in vivo
pretransplant Campath-1G for allogeneic transplantation in patients
with lymphoma. Blood 1999; 94 (Supl. 1): 394a.
48. Giralt S, Cohen A, Claxton D, Ueno N, Gajewski J, Khouri I et al. Fludarabine/Melphalan
as a less intense preparative regimen for unrelated
donor transplants in patients with hematologic malignancies. Blood
1998; 92 (Supl. 1): 289a.
49. Shimoni A, Anderlini P, Andersson B, Andreeff M, Brownschweig I,
Claxton D et al. Allogeneic transplantation for leukemia in patients bolder
than 60 years. Age should not exclude treatment with non-myeloablative
regimens. Blood 1999; 94 (Supl. 1): 710a.
50. Giralt S, Weber D, Aleman A, Anagnastopoulos A, Anderlini P,
Brownschweig I et al. Non-myeloablative conditioning with Fludarabine/Melphalan
for patients with multiple myeloma. Blood 1999;
94 (Supl. 1): 347a.
51. Molina A, McSweeney P, Maloney DG, Sandmayer B, Wagner JL, Nash
R et al. Degree of early donor T-cell chimerism predicts GVHD and graft
rejection in patients with non-myeloablative hematopoietic stem cell
allografts. Blood 1999; 94 (Supl. 1): 394a.
52. Childs R, Contentin N, Clave E, Bahceci E, Chernoff A, Linehan M et al.
Sustained regrassion of metastatic renal cell carcinoma following
non-myeloablative allogeneic peripheral blood stem cell transplantation:
a new application of allogeneic immunotherapy. Blood 1999;
94 (Supl. 1): 710a.
53. Barnes D, Loutit J. Treatment of murine leukaemia with X-rays and homologous
bone marrow. British J Haematol 1957; 3: 241-252.
54. Weiss L, Lubin I, Factorowich Y et al. Effective graft versus leukemnia effects
independently of graft versus host disease following T-cell depleted
allogeneic bone marrow transplantation in a murine model of B-cell
leukemia/lymphoma (BCL1). Role of cell therapy and rIL-2. J Immunol
1994; 153: 2562-2567.
55. Kolb HJ, Gunther W, Schumm M, Holler E, Wilmanns W, Thierfelder
S. Adoptive immunotherapy in canine chimeras. Transplantation 1997;
63: 430-436.
56. Johnson B, Truitt R. Delayed infusion of immunocompetent donor cells
after bone marrow transplantation breaks graft-host tolerance and
allows for persistent antileukemic reactivity without severe graft-versus-host
disease. Blood 1995; 85: 3302-3308.
57. Giralt S, Hester J, Huh Y, Hisch-Ginsberg CH, Rondon G, Seong D et al.
CD8-depleted donor lymphocyte infussion as treatment for relapsed
chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Blood 1995; 86: 4337-4343.